Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Erstveröffentlichung

2017

Authors

Hehlmann, R.

Lauseker, M.

Saussele, S.

Pfirrmann, M.

Krause, S.

et al.

Wissenschaftlicher Artikel

Published in

Leukemia ; 31 (2017), 11. - S. 2398-2406. - ISSN 0887-6924. - eISSN 1476-5551

Link to publication

https://dx.doi.org/10.1038/leu.2017.253

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: kinase inhibitor optimization | chronic-phase | european-leukemianet | molecular response | 800 mg | interferon-alpha | clinical-trials | expert panel | end-points | open-label
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record